|
|
|
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
|
|
|
|
|
Item 7.01.
|
Regulation FD Disclosure.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
Exhibit
No. |
|
Description
|
|
|
|
|
||
|
|
|
104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
|
ALDEYRA THERAPEUTICS, INC.
|
|
|
|
|
|
By:
|
/s/ Todd C. Brady
|
|
|
Name: Todd C. Brady, M.D., Ph.D.
|
|
|
Title: Chief Executive Officer
|
Exhibit 99.1 |
*;Q2YI '':DH/M3 0,"J4C/V;9D_8PW(YJ3
M[ /3BM86(["G_9OSI>T-%3L8K6H#3C)KY\_X*1?"8^//@9_PD=I#YFI^%I_M>
M5&6:V?"S+[X^5O\ @->+A<:YXYNK9J?NNVW9&<9>]J4OV]_V@[/1/V<=/M=
MO USXZB1;>1&^863('E?VRI5/^!GTJ#_ ()H_!L>"_A+=^-+Z#9JGBB0- 6'
MS)9QDA,?[[;F]QM]*^ /A_I/B3]HOQ]\/_
3*FQO,5\*G850U)(H;A;/
M[<4(Q*9(?XA_=JQ-.EQEM/C5KK'+-QMQ2]HT*5,UY2\FH>:6.V1=I53P#6KI
M]G%/H>HBZ)::(Y6,]5]"*Y[3=/77;^"66
N.'Q7F*WLC8^?-(UP[,?FXZ5U+#11Q2QDF=[<>-%Y^;-9T_C#>O$FWFN+>5
M]QJM-N8=\5LJ4%L8.O-[G7R^*-P_UN:A?Q /^>N?QKCV!Z9.*ADW;3CK5^S%
M[1OMC['VQS2?83UQ1S7+Y#*\OY<8Q33#^=:XL3
MUQ3FLAMI\R"QA26^ZJ\EG\V#R*Z)K&J\EF,'C-4I&4HW.?DLPW-5_LH!QCFM
MV6S!ZU7:T_/UJ^
U6:,Q%V:0'HQK1AWQ+M8
M_=X]Q4,8!DCD5/)*;B3>N!C[PK.5S*QZ#\/_$85A:32;T?@'T->A-'M
M/2O [5VL)EGCR.><5[;X6UA==T>*8
>E=/7BRC*#<9JS1SO308REC3?+/>O*OBS^U5\+
M/@C??8/%OBRVL]4P&_LZVC>YN%!Z%DC5B@QS\V,CI6%\-_VWO@Y\4M=AT32O
M%:V>L3MLAL]6MY+1I&)P%5G4(6)Z*&R